Reviews/Targeted Therapy Prostate Cancer/Overall survival benefit of androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer
Nmcrpc · PC-NMCRPC-02 · v2
This claim bundles three separate drugs and asks whether each one helps patients with this stage of prostate cancer live longer. For each drug there is one large, high-quality trial that directly measured how long patients lived and compared it against a dummy pill. Enzalutamide [1], darolutamide [2] (with a matching conference report [13]), and apalutamide [7] each showed patients lived longer, and each result met the trials' own pre-set bar for being a real difference rather than chance. The three trials were run separately and still pointed the same way. The panel judged the strongest objection, that many placebo patients later switched to the active drug or got other life-extending treatments, to work against the drugs rather than for them, so the survival gains appearing despite it were read as if anything an understatement.
Each limb of the three-drug claim is carried by a dedicated phase 3 double-blind placebo-controlled trial reporting a prespecified overall-survival result in this exact population. Enzalutamide extended median survival to 67.0 vs 56.3 months (HR 0.73, 95% CI 0.61-0.89, P=0.001) [1]; darolutamide raised 3-year survival to 83% vs 77% (HR 0.69, 95% CI 0.53-0.88, P=0.003) [2], corroborated by a 31% risk-of-death reduction in [13]; apalutamide extended median survival to 73.9 vs 59.9 months (HR 0.78, 95% CI 0.64-0.96, P=0.016) [7]. The three trials are independent in drug, sponsor, and protocol yet concordant in direction and magnitude (HR 0.69-0.78). The outcome measured is survival itself, so no surrogate inference is required. The contested point: The evidence does not divide against the claim; the panel's scrutiny instead concentrated on whether the apalutamide effect is as secure as the other two, since its survival interval upper bound sits at 0.96 [7], close to no effect. The Sceptic also noted that extensive crossover in ARAMIS and 19% crossover plus more subsequent therapy in SPARTAN [2][7] could in principle erode the comparison, but both the Sceptic and Moderator read this as biasing toward the null, not against the drugs.
All 16 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Targeted Therapy Prostate Cancer, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
ARAMIS unblinded all placebo patients to darolutamide and SPARTAN had 19% crossover plus more subsequent life-prolonging therapy in placebo arms; however this contaminates the placebo arm toward longer survival, biasing OS toward the null, so significant benefit despite it does not weaken the claim.
The apalutamide OS confidence interval (HR 0.78, 0.64-0.96) has an upper bound close to 1.0, indicating a more modest and less robust effect than the other two agents, though it still cleared prespecified significance.
Where it remains uncertain. The apalutamide survival interval reaches 0.96 [7], a more modest and less robust effect than the other two agents, though it still cleared its prespecified significance bar.
Aleatory
The apalutamide survival interval extends to 0.96 [7], so random sampling variation leaves its true effect compatible with values close to no benefit.
The load-bearing papers from a corpus of 16, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Carries the enzalutamide limb: significant OS benefit in nmCRPC (PROSPER).
“Median overall survival was 67.0 months (95% confidence interval [CI], 64.0 to not reached) in the enzalutamide group and 56.3 months (95% CI, 54.4 to 63.0) in the placebo group (hazard ratio for death, 0.73; 95% CI, 0.61 to 0.89; P = 0.001).”
Panel auditInternal validity: high · scope of inference: Men with nonmetastatic castration-resistant prostate cancer and PSA doubling time of 10 months or less, on androgen-deprivation therapy.Key limitations: industry funded · restricted to short PSA doubling time
Carries the darolutamide limb: significant OS benefit in nmCRPC (ARAMIS final analysis).
“The risk of death was significantly lower, by 31%, in the darolutamide group than in the placebo group (hazard ratio for death, 0.69; 95% CI, 0.53 to 0.88; P = 0.003).”
Panel auditInternal validity: high · scope of inference: Men with nonmetastatic castration-resistant prostate cancer and PSA doubling time 10 months or less, on androgen-deprivation therapy.Key limitations: placebo crossover after unblinding may dilute OS effect · industry funded
Carries the apalutamide limb: significant OS benefit in nmCRPC (SPARTAN final OS).
“Median OS was markedly longer with apalutamide versus placebo, reaching prespecified statistical significance (73.9 vs 59.9 mo, hazard ratio [HR]: 0.78 [95% confidence interval {CI}, 0.64-0.96]; p=0.016).”
Panel auditInternal validity: high · scope of inference: Men with nonmetastatic castration-resistant prostate cancer and PSA doubling time 10 months or less.Key limitations: placebo-to-apalutamide crossover · higher subsequent therapy in placebo arm
OS is listed among secondary endpoints with benefit asserted but no OS effect size, confidence interval or significance is reported in this primary MFS analysis.
Panel auditInternal validity: high · scope of inference: Men with nonmetastatic castration-resistant prostate cancer and PSA doubling time 10 months or less.Key limitations: OS immature at this analysis · OS only a secondary endpoint here, no numbers
4 of 16 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
All three conjuncts are carried by dedicated, concordant phase 3 RCTs reporting significant OS on the hard endpoint in the exact population, with residual concerns pointing toward conservatism rather than against the claim.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Independent replication of each survival result. Every limb rests on one pivotal trial; a confirmatory survival trial for any drug would move it from single-trial to replicated evidence, mattering most for apalutamide whose interval nears one [7]. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A second adequately powered phase 3 placebo-controlled or active-controlled survival trial per agent in this exact population.
Open question: Is the apalutamide overall-survival benefit robust given its confidence-interval upper bound of 0.96? Why it is still open: The apalutamide result [7] cleared prespecified significance but its interval reaches 0.96, and the corpus contains no second trial to confirm the magnitude.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 26 Oct 2026 · protocol v0.19